Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's Lymphoma (HL) in the ABVD therapeutic era

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 4, 2012, Pages 640-647

  Keller, Sarah F ^a   Kelly, Jennifer L ^a   Sensenig, Elizabeth ^b   Andreozzi, Jennifer ^a   Oliva, Jamie ^a   Rich, Lynn ^a   Constine, Louis ^a   Becker, Michael ^a   Phillips, Gordon ^a   Liesveld, Jane ^a   Fisher, Richard I ^a   Bernstein, Steven H ^a   Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

HD ASCT; Hematopoietic stem cells; Hodgkin lymphoma; Late effects of therapy; Relapsed and refractory disease

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MEPREDNISONE; VINBLASTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH DOSE AUTOLOGOUS STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; SALVAGE THERAPY; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; VINBLASTINE;

EID: 84858080091     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.08.012     Document Type: Article

References (44)

1. Duggan D.B., Petroni G.R., Johnson J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003, 21:607-614.
2. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341:1051-1054.
3. Reece D.E., Connors J.M., Spinelli J.J., et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994, 83:1193-1199.
4. Vose J.M., Bierman P.J., Anderson J.R., et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992, 80:2142-2148.
5. Bierman P.J., Vose J.M., Armitage J.O. Autologous transplantation for Hodgkin's disease: coming of age?. Blood 1994, 83:1161-1164.
6. Sweetenham J.W., Carella A.M., Taghipour G., et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999, 17:3101-3109.
7. Josting A., Katay I., Rueffer U., et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol 1998, 9:289-295.
8. Lazarus H.M., Rowlings P.A., Zhang M.J., et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999, 17:534-545.
9. Lazarus H.M., Loberiza F.R., Zhang M.J., et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001, 27:387-396.
10. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359:2065-2071.
11. David K.A., Mauro L., Evens A.M. Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. Curr Treat Options Oncol 2007, 8:352-374.
12. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program 2008, 326-333.
13. Moskowitz C.H., Kewalramani T., Nimer S.D., Gonzalez M., Zelenetz A.D., Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004, 124:645-652.
14. Lavoie J.C., Connors J.M., Phillips G.L., et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005, 106:1473-1478.
15. Smith S.D., Moskowitz C.H., Dean R., et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol 2011, 153:358-363.
16. Czyz J., Dziadziuszko R., Knopinska-Postuszuy W., et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004, 15:1222-1230.
17. Horning S.J., Chao N.J., Negrin R.S., et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997, 89:801-813.
18. Josting A., Rueffer U., Franklin J., Sieber M., Diehl V., Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000, 96:1280-1286.
19. Popat U., Hosing C., Saliba R.M., et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33:1015-1023.
20. Sureda A., Arranz R., Iriondo A., et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001, 19:1395-1404.
21. Deeg H.J., Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998, 91:1833-1844.
22. Forrest D.L., Nevill T.J., Naiman S.C., et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplant 2003, 32:915-923.
23. Forrest D.L., Hogge D.E., Nevill T.J., et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol 2005, 23:7994-8002.
24. Moskowitz A.J., Perales M.A., Kewalramani T., et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009, 146:158-163.
25. Horning S.J. Risk, cure and complications in advanced Hodgkin disease. Hematology Am Soc Hematol Educ Program 2007, 197-203.
26. National Death Index User's Manual 2010, U.S. Department of Health and Human Services PHS, Centers for Disease Control, National Center for Health Statistics, CDC, Hyattsville, MD.
27. Horm J. Assignment of Probabilistic Scores to National Death Index Record Matches. A-5-A-13. 12-1-1996. Centers for Disease Control and Prevention/National Center for Health Statistics National Death Index Plus: Coded Causes of Death, 1996.
28. Schemper M., Smith T.L. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
29. Mendler J.H., Kelly J., Voci S., et al. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008, 19:1759-1764.
30. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
31. Bierman P.J., Lynch J.C., Bociek R.G., et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002, 13:1370-1377.
32. Majhail N.S., Weisdorf D.J., Defor T.E., et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1065-1072.
33. Sirohi B., Cunningham D., Powles R., et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008, 19:1312-1319.
34. Stiff P.J., Unger J.M., Forman S.J., et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003, 9:529-539.
35. Canellos G.P. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?. Leukemia 1996, 10(Suppl 2):s68.
36. Bonadonna G., Zucali R., Monfardini S., De Lena M., Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252-259.
37. Viviani S., Di Nicola M., Bonfante V., et al. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma 2010, 51:1251-1259.
38. Connors J.M. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005, 23:6400-6408.
39. Diehl V., Franklin J., Hasenclever D., et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998, 16:3810-3821.
40. Engert A., Diehl V., Franklin J., et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009, 27:4548-4554.
41. Fung H.C., Stiff P., Schriber J., et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007, 13:594-600.
42. Jona A., Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev 2010, 24:233-238.
43. Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011, 117:4208-4217.
44. Forero-Torres A., Leonard J.P., Younes A., et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009, 146:171-179.